Description
ADU-1805 is an antibody-drug conjugate (ADC) that targets CEACAM5 (carcinoembryonic antigen), a protein highly expressed on colorectal cancer cells. The drug delivers a cytotoxic payload directly to cancer cells through selective binding to CEACAM5, allowing for targeted destruction of tumor tissue while minimizing damage to healthy cells.
Mechanism of Action
The antibody component binds specifically to CEACAM5 on cancer cell surfaces, facilitating internalization of the drug conjugate. Once in
Side Effects
Fatigue
Nausea
Decreased appetite
Diarrhea
Neutropenia
Anemia
Infusion reactions
Peripheral neuropathy
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT05856981
Phase 1
Recruiting
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
United States, Belgium, Spain